アジア太平洋の大腸癌(Colorectal Cancer)治療薬市場

◆英語タイトル:Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies
◆商品コード:GBIHC344MR
◆発行会社(リサーチ会社):GBI Research
◆発行日:2014年10月31日
◆ページ数:98
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆販売価格オプション(消費税別)
Single UserUSD4,995 ⇒換算¥519,480見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD9,990 ⇒換算¥1,038,960見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD14,985 ⇒換算¥1,558,440見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGBI Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GBI Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、アジア太平洋地域の大腸癌(Colorectal Cancer)治療薬市場について調査・分析し、イントロダクション、市販中の医薬品、パイプライン分析、治験動向、市場規模予測、市場の促進要因と阻害要因、事業提携・契約動向などの情報をお届けいたします。
【レポートの概要】

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 – Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 – Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies”, which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Colorectal Cancer (CRC). The market in the APAC region was worth an estimated $1.9 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% to $1.9 billion in 2020. The use of targeted therapies is expected to increase in the Asia-Pacific (APAC) markets (for the purposes of this report, APAC refers to Australia, China, India and Japan only), as patient access to these more expensive agents improves. The moderate uptake of late-stage pipeline products panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market. Others such as ramucirumab, TAS-102, TS-1, MelCancerVac will also contribute. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC CRC market.

Scope

The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the four APAC markets of Australia, China, India and Japan. It includes –
- A brief introduction to CRC, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms
- In-depth analysis of currently marketed drugs for CRC, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
- A comprehensive review of the pipeline for CRC, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
- Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
- Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
- Discussion of the drivers of and barriers to market growth
- In-depth analysis of all licensing and co-development deals that have occurred in the CRC market since 2006

Reasons to buy

The report will enhance your decision-making capability by allowing you to –
- Understand the CRC pipeline and the factors that indicate that it is becoming more innovative
- Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
- Follow the trends in CRC clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
- Observe the potential growth patterns expected for the CRC market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the CRC market
- Accelerate and strengthen your market position by identifying key companies for strategic partnerships

【レポートの目次】

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 8
2.1 Colorectal Cancer 8
2.2 Symptoms 8
2.3 Epidemiology 8
2.4 Pathophysiology 9
2.4.1 Histology 9
2.4.2 Genetic Basis 9
2.4.3 Etiology 9
2.5 Diagnosis 10
2.5.1 Digital Rectal Examination 11
2.5.2 Fecal Occult Blood Test 11
2.5.3 Flexible Sigmoidoscopy 11
2.5.4 Colonoscopy 11
2.5.5 Virtual Colonoscopy 12
2.5.6 Double Contrast Barium Enema 12
2.6 Prognosis and Disease Staging 12
2.7 Treatment Options 14
2.7.1 Surgery and Radiation Therapy 15
2.7.2 Chemotherapy 15
2.7.3 Targeted Therapies 15
2.7.4 Resistance to Pharmacological Therapies 16
2.7.5 Treatment Guidelines 17

3 Marketed Products 20
3.1 Key Marketed Products 20
3.1.1 Immunotherapies 20
3.1.2 Targeted Therapies 23
3.2 Hyperthermic Intraperitoneal Chemotherapy 28
3.3 Heat Map for Marketed Products 29

4 Pipeline Analysis 31
4.1 Overall Pipeline 31
4.1.1 Pipeline Analysis by Molecule Type 32
4.1.2 Pipeline Analysis by Mechanism of Action 33
4.2 Clinical Trials 35
4.2.1 Failure Rate 35
4.2.2 Clinical Trial Size 37
4.2.3 Duration 39
4.3 Promising Drug Candidates in Pipeline 41
4.3.1 Lonsurf (TAS-102 (tipiracil + trifluridine)) – Taiho Pharmaceutical 41
4.3.2 Cyramza – ramucirumab – Eli Lilly and Company 42
4.3.3 TS-1/Teysuno (tegafur + gimeracil + oteracil) – Taiho Pharmaceutical 42
4.3.4 CPP-1X (eflornithine hydrochloride) + sulindac – Cancer Prevention Pharmaceuticals 43
4.3.5 MelCancerVac – DanDrit Biotech 44
4.3.6 Xilonix – XBiotech 45
4.3.7 Nintedanib – Boehringer Ingelheim 45

5 Market Forecast to 2020 47
5.1 Asia-Pacific Market 47
5.1.1 Treatment Use Patterns 47
5.1.2 Market Size 47
5.2 Australia 48
5.2.1 Treatment Use Patterns 48
5.2.2 Annual Cost of Therapy 49
5.2.3 Market Size 50
5.3 India 51
5.3.1 Treatment Use Patterns 51
5.3.2 Annual Cost of Therapy 52
5.3.3 Market Size 53
5.4 China 54
5.4.1 Treatment Use Patterns 54
5.4.2 Annual Cost of Therapy 55
5.4.3 Market Size 56
5.5 Japan 57
5.5.1 Treatment Use Patterns 57
5.5.2 Annual Cost of Therapy 58
5.5.3 Market Size 59
5.6 Drivers and Barriers 60
5.6.1 Drivers 60
5.6.2 Barriers 62

6 Deals and Strategic Consolidations 63
6.1 Licensing Agreements 63
6.1.1 Major Licensing Deals 64
6.2 Co-development Agreements 65
6.2.1 Major Co-development Agreements 67

7 Appendix 68
7.1 All Pipeline Drugs by Phase 68
7.1.1 Discovery 68
7.1.2 Preclinical 70
7.1.3 IND/CTA-Filed 75
7.1.4 Phase I 76
7.1.5 Phase II 80
7.1.6 Phase III 85
7.2 Market Forecasts to 2020 86
7.2.1 Asia-Pacific 86
7.2.2 Australia 86
7.2.3 India 86
7.2.4 China 87
7.2.5 Japan 87
7.3 Market Definitions 87
7.4 Abbreviations 87
7.5 References 91
7.6 Research Methodology 94
7.6.1 Coverage 94
7.6.2 Secondary Research 94
7.6.3 Primary Research 95
7.6.4 Therapeutic Landscape 95
7.6.5 Geographical Landscape 98
7.6.6 Pipeline Analysis 98
7.7 Expert Panel Validation 98
7.8 Contact Us 98
7.9 Disclaimer 98

[List of Tables]
Table 1 Colorectal Cancer Therapeutics, Global, TNM Staging, 2013 14
Table 2 Surgical Options for Colorectal Cancer 15
Table 3 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2014 68
Table 4 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2014 70
Table 5 Colorectal Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed), 2013 75
Table 6 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2014 76
Table 7 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2014 80
Table 8 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2014 85
Table 9 Colorectal Cancer Therapeutics, Asia-Pacific, Forecast Data, 2013–2020 86
Table 10 Colorectal Cancer Therapeutics, Australia, Forecast Data, 2013–2020 86
Table 11 Colorectal Cancer Therapeutics, India, Forecast Data, 2013–2020 86
Table 12 Colorectal Cancer Therapeutics, China, Forecast Data, 2013–2020 87
Table 13 Colorectal Cancer Therapeutics, Japan, Forecast Data, 2013–2020 87

[List of Figures]
Figure 1: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage I to III) 17
Figure 2: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage IV) 18
Figure 3: Colorectal Cancer Therapeutics, Global, Heat Map (Marketed Products) 30
Figure 4: Colorectal Cancer Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2013 31
Figure 5: Colorectal Cancer Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2013 32
Figure 6: Colorectal Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of Development, 2013 34
Figure 7: Colorectal Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2013 36
Figure 8: Colorectal Cancer Therapeutics, Global, Clinical Trial Size, 2013 38
Figure 9: Colorectal Cancer Therapeutics, Global, Clinical Trial Duration (months), 2013 40
Figure 10: Colorectal Cancer Therapeutics, Asia-Pacific, Treatment Use Patterns (‘000) ,2013–2020 47
Figure 11: Colorectal Cancer Therapeutics, Asia-Pacific, Market Size ($bn), 2013–2020 48
Figure 12: Colorectal Cancer Therapeutics, Australia, Treatment Use Patterns (‘000), 2013–2020 49
Figure 13: Colorectal Cancer Therapeutics, Australia, Annual Cost of Therapy ($), 2013–2020 50
Figure 14: Colorectal Cancer Therapeutics, Australia, Market Size ($m), 2013–2020 51
Figure 15: Colorectal Cancer Therapeutics, India, Treatment Use Patterns (‘000), 2013–2020 52
Figure 16: Colorectal Cancer Therapeutics, India, Annual Cost of Therapy ($), 2013–2020 53
Figure 17: Colorectal Cancer Therapeutics, India, Market Size ($m), 2013–2020 54
Figure 18: Colorectal Cancer Therapeutics, China, Treatment Use Patterns (‘000), 2013–2020 55
Figure 19: Colorectal Cancer Therapeutics, China, Annual Cost of Therapy ($), 2013–2020 56
Figure 20: Colorectal Cancer Therapeutics, China, Market Size ($m), 2013–2020 57
Figure 21: Colorectal Cancer Therapeutics, Japan, Treatment Use Patterns (‘000), 2013–2020 58
Figure 22: Colorectal Cancer Therapeutics, Japan, Annual Cost of Therapy ($), 2013–2020 59
Figure 23: Colorectal Cancer Therapeutics, Japan, Market Size, 2013–2020 60
Figure 24: Colorectal Cancer Therapeutics, Global, Licensing Deals by Geography, 2006–2014 63
Figure 25: Colorectal Cancer Therapeutics, Global, Licensing Deals by Phase, Value, Mechanism of Action, 2006–2014 64
Figure 26: Colorectal Cancer Market, Global, Co-development Deals by Geography and by Value, 2006–2014 66
Figure 27: GBI Research Market Forecasting Model 97

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アジア太平洋の大腸癌(Colorectal Cancer)治療薬市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆